AustralieFrV1, Main, Exploration, bibRecord, 000663

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation

Identifieur interne : 000663 ( Main/Exploration ); précédent : 000662; suivant : 000664

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation

Auteurs : Franck E. Nicolini ; Grzegorz W. Basak ; Dong-Wook Kim ; Eduardo Olavarria ; Javier Pinilla-Ibarz ; Jane F. Apperley ; Timothy Hughes ; Dietger Niederwieser ; Michael J. Mauro ; Charles Chuah ; Andreas Hochhaus ; Giovanni Martinelli ; Maral Dersarkissian ; Mei Sheng Duh ; Lisa J. Mcgarry ; Hagop M. Kantarjian ; Jorge E. Cortes

Source :

Cancer [ 0008-543X ] ; 2017.

RBID : PMC:5573914

Descripteurs français

English descriptors

KwdEn :
- Adult, Aged, Antineoplastic Agents (therapeutic use), Blast Crisis (genetics), Blast Crisis (therapy), Female, Humans, Imidazoles (therapeutic use), Kaplan-Meier Estimate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics), Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy), Male, Middle Aged, Multivariate Analysis, Mutation, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics), Precursor Cell Lymphoblastic Leukemia-Lymphoma (therapy), Proportional Hazards Models, Pyridazines (therapeutic use), Retrospective Studies, Stem Cell Transplantation (methods), Survival Rate, Transplantation, Homologous, Treatment Outcome.
MESH :
- chemical , therapeutic use : Antineoplastic Agents, Imidazoles, Pyridazines.
- genetics : Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- methods : Stem Cell Transplantation.
- therapy : Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- Adult, Aged, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Mutation, Philadelphia Chromosome, Proportional Hazards Models, Retrospective Studies, Survival Rate, Transplantation, Homologous, Treatment Outcome.

Abstract

BACKGROUND

Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia‐positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell transplantation (allo‐SCT).

METHODS

A post hoc, retrospective, indirect comparison of OS among patients who received single‐agent ponatinib in the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial with those who underwent allo‐SCT as reported to the European Bone Marrow Transplant registry, stratified by CML disease phase and Ph+ ALL, was conducted. Kaplan‐Meier survival curves and multivariate Cox proportional‐hazards models were used to compare OS between intervention groups, adjusting for time from diagnosis to intervention, age, sex, and geographic region; 24‐month and 48‐month OS rates and median OS were reported.

RESULTS

After adjustment for potential confounders, 24‐month and 48‐month OS rates were significantly higher in patients with chronic‐phase CML (CP‐CML) who received ponatinib compared with those who underwent allo‐SCT (24 months: 84% vs 60.5%, respectively; P = .004; 48 months: 72.7% vs 55.8%, respectively; P = .013), with a hazard ratio (HR) of 0.37 (95% confidence interval [CI], 0.16‐0.84; P = .017). In patients who had accelerated‐phase CML, OS rates were not significantly different between the groups (HR, 0.90; 95% CI, 0.20‐4.10; P = .889). In patients who had blast‐crisis CML and those with Ph+ ALL, ponatinib was associated with shorter OS compared with allo‐SCT (blast‐crisis CML: HR, 2.29 [95% CI, 1.08‐4.82; P = .030]; Ph+ ALL: HR, 2.77 [95% CI, 0.73‐10.56; P = .146]).

CONCLUSIONS

Although allo‐SCT remains an important treatment option for patients with T315I‐positive advanced CML and Ph+ ALL, ponatinib represents a valuable alternative for patients with T315I‐positive CP‐CML. Cancer 2017;123:2875–80. © 2017 American Cancer Society.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573914

DOI: 10.1002/cncr.30558
PubMed: 28387926
PubMed Central: 5573914

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation</title>
<author><name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E." last="Nicolini">Franck E. Nicolini</name>
<affiliation><nlm:aff id="cncr30558-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Basak, Grzegorz W" sort="Basak, Grzegorz W" uniqKey="Basak G" first="Grzegorz W." last="Basak">Grzegorz W. Basak</name>
<affiliation><nlm:aff id="cncr30558-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kim, Dong Ook" sort="Kim, Dong Ook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name>
<affiliation><nlm:aff id="cncr30558-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Olavarria, Eduardo" sort="Olavarria, Eduardo" uniqKey="Olavarria E" first="Eduardo" last="Olavarria">Eduardo Olavarria</name>
<affiliation><nlm:aff id="cncr30558-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Pinilla Barz, Javier" sort="Pinilla Barz, Javier" uniqKey="Pinilla Barz J" first="Javier" last="Pinilla-Ibarz">Javier Pinilla-Ibarz</name>
<affiliation><nlm:aff id="cncr30558-aff-0005"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
<affiliation><nlm:aff id="cncr30558-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name>
<affiliation><nlm:aff id="cncr30558-aff-0006"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name>
<affiliation><nlm:aff id="cncr30558-aff-0007"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mauro, Michael J" sort="Mauro, Michael J" uniqKey="Mauro M" first="Michael J." last="Mauro">Michael J. Mauro</name>
<affiliation><nlm:aff id="cncr30558-aff-0008"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Chuah, Charles" sort="Chuah, Charles" uniqKey="Chuah C" first="Charles" last="Chuah">Charles Chuah</name>
<affiliation><nlm:aff id="cncr30558-aff-0009"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name>
<affiliation><nlm:aff id="cncr30558-aff-0010"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Martinelli, Giovanni" sort="Martinelli, Giovanni" uniqKey="Martinelli G" first="Giovanni" last="Martinelli">Giovanni Martinelli</name>
<affiliation><nlm:aff id="cncr30558-aff-0011"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dersarkissian, Maral" sort="Dersarkissian, Maral" uniqKey="Dersarkissian M" first="Maral" last="Dersarkissian">Maral Dersarkissian</name>
<affiliation><nlm:aff id="cncr30558-aff-0012"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Duh, Mei Sheng" sort="Duh, Mei Sheng" uniqKey="Duh M" first="Mei Sheng" last="Duh">Mei Sheng Duh</name>
<affiliation><nlm:aff id="cncr30558-aff-0012"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mcgarry, Lisa J" sort="Mcgarry, Lisa J" uniqKey="Mcgarry L" first="Lisa J." last="Mcgarry">Lisa J. Mcgarry</name>
<affiliation><nlm:aff id="cncr30558-aff-0013"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M." last="Kantarjian">Hagop M. Kantarjian</name>
<affiliation><nlm:aff id="cncr30558-aff-0014"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E." last="Cortes">Jorge E. Cortes</name>
<affiliation><nlm:aff id="cncr30558-aff-0014"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">28387926</idno>
<idno type="pmc">5573914</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573914</idno>
<idno type="RBID">PMC:5573914</idno>
<idno type="doi">10.1002/cncr.30558</idno>
<date when="2017">2017</date>
<idno type="wicri:Area/Pmc/Corpus">002364</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002364</idno>
<idno type="wicri:Area/Pmc/Curation">002214</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002214</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000163</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000163</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000843</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000843</idno>
<idno type="wicri:Area/PubMed/Curation">000840</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000840</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000840</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000840</idno>
<idno type="wicri:Area/Ncbi/Merge">004604</idno>
<idno type="wicri:Area/Ncbi/Curation">004604</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004604</idno>
<idno type="wicri:doubleKey">0008-543X:2017:Nicolini F:overall:survival:with</idno>
<idno type="wicri:Area/Main/Merge">000658</idno>
<idno type="wicri:Area/Main/Curation">000663</idno>
<idno type="wicri:Area/Main/Exploration">000663</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation</title>
<author><name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E." last="Nicolini">Franck E. Nicolini</name>
<affiliation><nlm:aff id="cncr30558-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Basak, Grzegorz W" sort="Basak, Grzegorz W" uniqKey="Basak G" first="Grzegorz W." last="Basak">Grzegorz W. Basak</name>
<affiliation><nlm:aff id="cncr30558-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kim, Dong Ook" sort="Kim, Dong Ook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name>
<affiliation><nlm:aff id="cncr30558-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Olavarria, Eduardo" sort="Olavarria, Eduardo" uniqKey="Olavarria E" first="Eduardo" last="Olavarria">Eduardo Olavarria</name>
<affiliation><nlm:aff id="cncr30558-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Pinilla Barz, Javier" sort="Pinilla Barz, Javier" uniqKey="Pinilla Barz J" first="Javier" last="Pinilla-Ibarz">Javier Pinilla-Ibarz</name>
<affiliation><nlm:aff id="cncr30558-aff-0005"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
<affiliation><nlm:aff id="cncr30558-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name>
<affiliation><nlm:aff id="cncr30558-aff-0006"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name>
<affiliation><nlm:aff id="cncr30558-aff-0007"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mauro, Michael J" sort="Mauro, Michael J" uniqKey="Mauro M" first="Michael J." last="Mauro">Michael J. Mauro</name>
<affiliation><nlm:aff id="cncr30558-aff-0008"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Chuah, Charles" sort="Chuah, Charles" uniqKey="Chuah C" first="Charles" last="Chuah">Charles Chuah</name>
<affiliation><nlm:aff id="cncr30558-aff-0009"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name>
<affiliation><nlm:aff id="cncr30558-aff-0010"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Martinelli, Giovanni" sort="Martinelli, Giovanni" uniqKey="Martinelli G" first="Giovanni" last="Martinelli">Giovanni Martinelli</name>
<affiliation><nlm:aff id="cncr30558-aff-0011"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dersarkissian, Maral" sort="Dersarkissian, Maral" uniqKey="Dersarkissian M" first="Maral" last="Dersarkissian">Maral Dersarkissian</name>
<affiliation><nlm:aff id="cncr30558-aff-0012"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Duh, Mei Sheng" sort="Duh, Mei Sheng" uniqKey="Duh M" first="Mei Sheng" last="Duh">Mei Sheng Duh</name>
<affiliation><nlm:aff id="cncr30558-aff-0012"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mcgarry, Lisa J" sort="Mcgarry, Lisa J" uniqKey="Mcgarry L" first="Lisa J." last="Mcgarry">Lisa J. Mcgarry</name>
<affiliation><nlm:aff id="cncr30558-aff-0013"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M." last="Kantarjian">Hagop M. Kantarjian</name>
<affiliation><nlm:aff id="cncr30558-aff-0014"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E." last="Cortes">Jorge E. Cortes</name>
<affiliation><nlm:aff id="cncr30558-aff-0014"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Cancer</title>
<idno type="ISSN">0008-543X</idno>
<idno type="eISSN">1097-0142</idno>
<imprint><date when="2017">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Blast Crisis (genetics)</term>
<term>Blast Crisis (therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Imidazoles (therapeutic use)</term>
<term>Kaplan-Meier Estimate</term>
<term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics)</term>
<term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multivariate Analysis</term>
<term>Mutation</term>
<term>Philadelphia Chromosome</term>
<term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics)</term>
<term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (therapy)</term>
<term>Proportional Hazards Models</term>
<term>Pyridazines (therapeutic use)</term>
<term>Retrospective Studies</term>
<term>Stem Cell Transplantation (methods)</term>
<term>Survival Rate</term>
<term>Transplantation, Homologous</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse multivariée</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Chromosome Philadelphie</term>
<term>Crise blastique ()</term>
<term>Crise blastique (génétique)</term>
<term>Estimation de Kaplan-Meier</term>
<term>Femelle</term>
<term>Humains</term>
<term>Imidazoles (usage thérapeutique)</term>
<term>Leucémie myéloïde chronique BCR-ABL positive ()</term>
<term>Leucémie myéloïde chronique BCR-ABL positive (génétique)</term>
<term>Leucémie-lymphome lymphoblastique à précurseurs B et T ()</term>
<term>Leucémie-lymphome lymphoblastique à précurseurs B et T (génétique)</term>
<term>Modèles de hasards proportionnels</term>
<term>Mutation</term>
<term>Mâle</term>
<term>Pyridazines (usage thérapeutique)</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Taux de survie</term>
<term>Transplantation de cellules souches ()</term>
<term>Transplantation homologue</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Imidazoles</term>
<term>Pyridazines</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Blast Crisis</term>
<term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term>
<term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Crise blastique</term>
<term>Leucémie myéloïde chronique BCR-ABL positive</term>
<term>Leucémie-lymphome lymphoblastique à précurseurs B et T</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Stem Cell Transplantation</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Blast Crisis</term>
<term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term>
<term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Imidazoles</term>
<term>Pyridazines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multivariate Analysis</term>
<term>Mutation</term>
<term>Philadelphia Chromosome</term>
<term>Proportional Hazards Models</term>
<term>Retrospective Studies</term>
<term>Survival Rate</term>
<term>Transplantation, Homologous</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse multivariée</term>
<term>Chromosome Philadelphie</term>
<term>Crise blastique</term>
<term>Estimation de Kaplan-Meier</term>
<term>Femelle</term>
<term>Humains</term>
<term>Leucémie myéloïde chronique BCR-ABL positive</term>
<term>Leucémie-lymphome lymphoblastique à précurseurs B et T</term>
<term>Modèles de hasards proportionnels</term>
<term>Mutation</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Taux de survie</term>
<term>Transplantation de cellules souches</term>
<term>Transplantation homologue</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="cncr30558-sec-0001"><title>BACKGROUND</title>
<p>Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia‐positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell transplantation (allo‐SCT).</p>
</sec>
<sec id="cncr30558-sec-0002"><title>METHODS</title>
<p>A post hoc, retrospective, indirect comparison of OS among patients who received single‐agent ponatinib in the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial with those who underwent allo‐SCT as reported to the European Bone Marrow Transplant registry, stratified by CML disease phase and Ph+ ALL, was conducted. Kaplan‐Meier survival curves and multivariate Cox proportional‐hazards models were used to compare OS between intervention groups, adjusting for time from diagnosis to intervention, age, sex, and geographic region; 24‐month and 48‐month OS rates and median OS were reported.</p>
</sec>
<sec id="cncr30558-sec-0003"><title>RESULTS</title>
<p>After adjustment for potential confounders, 24‐month and 48‐month OS rates were significantly higher in patients with chronic‐phase CML (CP‐CML) who received ponatinib compared with those who underwent allo‐SCT (24 months: 84% vs 60.5%, respectively; <italic>P</italic>
 = .004; 48 months: 72.7% vs 55.8%, respectively; <italic>P</italic>
 = .013), with a hazard ratio (HR) of 0.37 (95% confidence interval [CI], 0.16‐0.84; <italic>P</italic>
 = .017). In patients who had accelerated‐phase CML, OS rates were not significantly different between the groups (HR, 0.90; 95% CI, 0.20‐4.10; <italic>P</italic>
 = .889). In patients who had blast‐crisis CML and those with Ph+ ALL, ponatinib was associated with shorter OS compared with allo‐SCT (blast‐crisis CML: HR, 2.29 [95% CI, 1.08‐4.82; <italic>P</italic>
 = .030]; Ph+ ALL: HR, 2.77 [95% CI, 0.73‐10.56; <italic>P</italic>
 = .146]).</p>
</sec>
<sec id="cncr30558-sec-0004"><title>CONCLUSIONS</title>
<p>Although allo‐SCT remains an important treatment option for patients with T315I‐positive advanced CML and Ph+ ALL, ponatinib represents a valuable alternative for patients with T315I‐positive CP‐CML. <bold><italic>Cancer</italic>
 2017;123:2875–80.</bold>
 © <italic>2017 American Cancer Society</italic>
.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
<name sortKey="Basak, Grzegorz W" sort="Basak, Grzegorz W" uniqKey="Basak G" first="Grzegorz W." last="Basak">Grzegorz W. Basak</name>
<name sortKey="Chuah, Charles" sort="Chuah, Charles" uniqKey="Chuah C" first="Charles" last="Chuah">Charles Chuah</name>
<name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E." last="Cortes">Jorge E. Cortes</name>
<name sortKey="Dersarkissian, Maral" sort="Dersarkissian, Maral" uniqKey="Dersarkissian M" first="Maral" last="Dersarkissian">Maral Dersarkissian</name>
<name sortKey="Duh, Mei Sheng" sort="Duh, Mei Sheng" uniqKey="Duh M" first="Mei Sheng" last="Duh">Mei Sheng Duh</name>
<name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name>
<name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name>
<name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M." last="Kantarjian">Hagop M. Kantarjian</name>
<name sortKey="Kim, Dong Ook" sort="Kim, Dong Ook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name>
<name sortKey="Martinelli, Giovanni" sort="Martinelli, Giovanni" uniqKey="Martinelli G" first="Giovanni" last="Martinelli">Giovanni Martinelli</name>
<name sortKey="Mauro, Michael J" sort="Mauro, Michael J" uniqKey="Mauro M" first="Michael J." last="Mauro">Michael J. Mauro</name>
<name sortKey="Mcgarry, Lisa J" sort="Mcgarry, Lisa J" uniqKey="Mcgarry L" first="Lisa J." last="Mcgarry">Lisa J. Mcgarry</name>
<name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E." last="Nicolini">Franck E. Nicolini</name>
<name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name>
<name sortKey="Olavarria, Eduardo" sort="Olavarria, Eduardo" uniqKey="Olavarria E" first="Eduardo" last="Olavarria">Eduardo Olavarria</name>
<name sortKey="Pinilla Barz, Javier" sort="Pinilla Barz, Javier" uniqKey="Pinilla Barz J" first="Javier" last="Pinilla-Ibarz">Javier Pinilla-Ibarz</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000663 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000663 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:5573914
   |texte=   Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28387926" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.